Safety Reading Notes

Read safety context beside the research guide.

The Virodhamine source set includes safety-context rows around virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 26408156

Mechanistic research summary: insufficient (3), mechanistic or pharmacological (8)

PubMed For Dummies Article

Virodhamine Evidence Review: the long-form source walk-through

Quick read
  • Virodhamine currently has 11 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 26408156
  • The evidence classes most visible in the row language are mechanistic or pharmacological (8), and insufficient (3). PMID 17876300
  • The study-design language most visible in the row language is Cellular or in vitro study (5), Narrative or expert review (3), and Animal study (3). PMID 18514375
  • The repeated topics are virodhamine biology, receptor pharmacology, metabolism, physiology, or safety... (11), which tells the reader where to start opening PubMed and DOI links. PMID 18806815

Start with the research question

Virodhamine is built from 11 source-backed evidence row(s) and 11 research source(s). The current evidence classes read as mechanistic or pharmacological (8), and insufficient (3), and the study-design language most often reads as Cellular or in vitro study (5), Narrative or expert review (3), and Animal study (3). PMID 26408156

The row-level question is not simply whether Virodhamine is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are virodhamine biology, receptor pharmacology, metabolism, physiology, or safety... (11). PMID 26408156

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 12023533

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 22454039

Mechanistic evidence 8 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 32696508

Limits and uncertainty 3 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 15233865

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 29958841

Where this page has the most source density

The largest bucket surfaced for this page is virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is the next evidence bucket, which gives readers another way to see what the literature repeatedly circles. PMID 26408156

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 26408156

Bucket chapters: what the literature is circling

virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

11 research sources 11 rows (1156-1166) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (8)

Virodhamine appears in rows studying virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 11 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 26408156

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 26408156

  • Evidence row 1156

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: N... PMID 26408156

  • Evidence row 1166

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients ment... PMID 19255745

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (8 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 26408156

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 26408156

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 23789792
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 19255745
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 26408156

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 26408156

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 26408156

Source-reading checklist for Virodhamine

  1. Open the linked PubMed or DOI record. PMID 17876300
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 18514375
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 18806815
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 12023533
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 22454039

Source Notes

Virodhamine source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1156

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 26408156

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Endocannabinoids and Their Pharmacological Actions.
  2. Evidence row 1157

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17876300

    Evidence class: insufficient; Study design: Narrative or expert review. Source: GPR55: a new member of the cannabinoid receptor clan?
  3. Evidence row 1158

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 18514375

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The role of the CB1 receptor in the regulation of sleep.
  4. Evidence row 1159

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 18806815

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product.
  5. Evidence row 1160

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 12023533

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
  6. Evidence row 1161

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 22454039

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55.
  7. Evidence row 1162

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 32696508

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Virodhamine, an endocannabinoid, induces megakaryocyte differentiation by regulating MAPK activity and function of mitochondria.
  8. Evidence row 1163

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 15233865

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery.
  9. Evidence row 1164

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 29958841

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.
  10. Evidence row 1165

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 23789792

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Mechanism of platelet activation induced by endocannabinoids in blood and plasma.
  11. Evidence row 1166

    Virodhamine studied for virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: virodhamine biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 19255745

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: (Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.